1. Home
  2. MTCH vs TGTX Comparison

MTCH vs TGTX Comparison

Compare MTCH & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Match Group Inc.

MTCH

Match Group Inc.

HOLD

Current Price

$37.97

Market Cap

9.1B

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$52.85

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTCH
TGTX
Founded
1986
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1B
8.5B
IPO Year
2004
2008

Fundamental Metrics

Financial Performance
Metric
MTCH
TGTX
Price
$37.97
$52.85
Analyst Decision
Hold
Strong Buy
Analyst Count
12
5
Target Price
$35.17
$49.80
AVG Volume (30 Days)
3.6M
2.5M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
2.16%
N/A
EPS Growth
17.82
1746.67
EPS
0.68
0.12
Revenue
$3,487,197,000.00
$2,785,000.00
Revenue This Year
$2.15
$49.08
Revenue Next Year
$3.82
$26.69
P/E Ratio
$55.93
$439.00
Revenue Growth
0.22
N/A
52 Week Low
$28.81
$25.37
52 Week High
$41.03
$59.30

Technical Indicators

Market Signals
Indicator
MTCH
TGTX
Relative Strength Index (RSI) 50.46 50.66
Support Level $37.56 $51.15
Resistance Level $39.36 $58.34
Average True Range (ATR) 1.16 2.38
MACD -0.10 -0.89
Stochastic Oscillator 23.66 23.07

Price Performance

Historical Comparison
MTCH
TGTX

About MTCH Match Group Inc.

Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. It generates the majority of its revenue from the Tinder segment.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: